2022-502871-49-00招募中1 期
Evaluation of tolerance and pharmacokinetics profile of high dose favipiravir in healthy volunteers - FAVIDOSE
Institut National De La Sante Et De La Recherche Medicale1 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2023年4月25日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 39
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Pr Denis MALVY
Scientific
Institut National De La Sante Et De La Recherche Medicale
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
To evaluate the pharmakcokinetics, tolerability and short term safety of ciprofloxacin in neonates and infants with suspected (or proven) Gram Negative Infection Open Label pilot PK study - TINN Treat Infections in Neonates Program(TINN-PK) - TINN Treat Infections in Neonates Pharmocokinetics of CiprofloxaciEUCTR2010-019955-23-GBiverpool Women's NHS Foundation Trust
进行中（未招募）
不适用
Pharmacokinetics and Tolerability of AV104 (Nalmefene hydrochloride) buccal films in Cholestatic Liver Disease Subjects.CTRI/2022/05/042461Avior Bio Inc
已完成
1 期
Pharmacokinetics of lEvofloxacin FORmulations in children with MDR-TB exposure (PERFORM)TuberculosisPACTR202008476090763Stellenbosch University Tygerberg Hospital24
进行中（未招募）
1 期
Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV)in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive. Revised Protocol 02, incorporating Protocol Amendment 01 (v1.0, date 18-Apr-2008), and Protocol Amendment 04 (v1.0, date 05-Dec-2008).Chronic Hepatitis B Virus (HBV) InfectionMedDRA version: 8.1Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)EUCTR2005-005816-26-BEBristol-Myers Squibb International Corporation64
进行中（未招募）
1 期
A study of Entecavir in Pediatric Patients with Chronic Hepatitis B Virus (HBV) InfectioChronic Hepatitis B Virus (HBV) InfectionMedDRA version: 16.1 Level: LLT Classification code 10019743 Term: Hepatitis B virus (HBV) System Organ Class: 100000004848EUCTR2005-005816-26-GBBristol-Myers Squibb International Corporation64